While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
- Shionogi’s COVID Pill Effective for Non-Omicron Variants Too: President
October 14, 2022
- Fertility Drugs Face Supply Woes as Demand Spikes on Health Coverage
October 14, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Tailored Vaccine for Ages 5-11
October 13, 2022
- Shionogi Delays Filing Plan for COVID-19 Vaccine to “By End of 2022”
October 13, 2022
- Shionogi to Test COVID Pill as Prophylaxis for Household Contacts from December
October 13, 2022
- Takeda to Discontinue Zejula Capsules, Urges Switch to Tablet Version
October 12, 2022
- Viatris Group to End Sale of 33 Products for Various Reasons
October 12, 2022
- Teikoku Seiyaku Pulls Plug on Kampo Business
October 12, 2022
- Kyushu Univ. Spinoff Aims to File NK-Like Cells in 2025, Eyes Combo with Checkpoint Drugs
October 11, 2022
- Daiichi Sankyo Employee Indicted for Death of Wife by Poisoning
October 11, 2022
- Japan Ethical Drug Sales Rise 6.3% in August: Crecon
October 11, 2022
- Moderna Probing Correlations between Spikevax Adverse Reactions and Immune Response: SVP
October 7, 2022
- Opdivo Top-Selling Drug in Japan for 9 Consecutive Months: Encise
October 7, 2022
- Santen’s Glaucoma Drug Accepted for Review in Europe
October 7, 2022
- Fujifilm to Launch Domestic Bio-CDMO Site in FY2026 to Bolster Vaccine Production
October 7, 2022
- Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
October 7, 2022
- Towa’s Win in Livalo Damage Suit Now Final and Binding
October 7, 2022
- Kyowa Kirin’s Venture Fund Invests in Cellarity
October 6, 2022
- Shionogi, UN Agency Tie Up for Generic Distribution of COVID Pill in Low-Middle-Income Nations
October 5, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…